Publication | Open Access

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

OncologyElderly PatientsMedicineAge ≥70 YearsMetronomic TherapyFirst-line TreatmentPharmacotherapyCancer TreatmentPharmacologyLung Cancer